Women’s health Archives - Page 3 of 6

Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference

John C Stevenson MB BS, FRCP, FESC, MFSEM, Serge Rozenberg MD, PhD, Silvia Maffei MD, Christian Egarter Prof Dr Med, Petra Stute Prof Dr Med, Thomas Römer Prof Dr Med

Article Type

Review

Published

02 Dec 2020

This narrative review examines the role of progestogens in MHT, with the aim of providing practical recommendations for prescribing physicians.

Potential risk of drug–drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV

Milena M Murray PharmD, MSc, Ashley Jensen PharmD, Thomas Cieslik PharmD Candidate, Susan E Cohn MD, MPH

Article Type

Original Research

Published

05 Aug 2020

The objectives of this study were to assess antiretroviral therapy and hormonal contraceptive use among women living with HIV and quantify the frequency of potential drug–drug interactions between antiretroviral therapy and hormonal contraceptives.

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies

Ana Rosa Jurado López MD, PhD, Francisca Molero Rodríguez MD

Article Type

Case Report

Published

01 Jul 2020

The case studies presented in this article follow the progress of two women who began treatment with ospemifene for the main presenting symptom of dyspareunia.

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies

Félix Lugo Salcedo MD, Zuramis Estrada Blanco MD

Article Type

Case Report

Published

01 Jul 2020

This article reports the clinical course of two women with dyspareunia preventing sexual intercourse who were treated with ospemifene and laser therapy.

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

Article Type

Case Report

Published

01 Jul 2020

The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.